Gefticip 250mg Tablet (Gefitinib) – First-Line EGFR Lung Cancer Targeted Therapy

Gefticip 250 (Gefitinib) (generic equivalent to Iressa) is a prescription targeted oncology medication for the treatment of locally advanced or metastatic NSCLC with activating EGFR mutations. As a targeted therapy, it works at a molecular level to slow cancer cell proliferation while sparing healthy tissue.

Composition: Gefitinib (250mg)

Manufacturer: Cipla Ltd

Prescription-only oncology medication. Use only under the direct supervision of a licensed oncologist. Regular blood tests and monitoring are mandatory throughout treatment.

Composition	Gefitinib (250mg)
Dosage Form	Tablets
Equivalent brand	Iressa
Generic Name	Gefitinib
Indication	Non-small cell lung cancer, Pancreatic cancer
Manufacturer	Cipla Ltd
Packaging	30 tablets in 1 bottle

RxMed Kart's sole intention is to ensure that its consumers get expert-reviewed, accurate, and trustworthy information. However, the information contained herein should NOT use as a substitute for a qualified physician's advice. The information provided here is for informational purposes only. This may not cover all possible side effects, drug interactions, or warnings or alerts. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.

$135.00

Pack Size

Quantity

Gefticip 250mg Tablet (Gefitinib) – First-Line EGFR Lung Cancer Targeted Therapy

Additional information

Disclaimer